Hyperfine (HYPR) Competitors

Hyperfine (NASDAQ:HYPR) and NeuroPace (NASDAQ:NPCE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, community ranking, media sentiment, analyst recommendations, dividends and profitability.

Is HYPR or NPCE more profitable?

NeuroPace has a net margin of -36.74% compared to Hyperfine's net margin of -309.42%. Hyperfine's return on equity of -57.54% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperfine	-309.42%	-57.54%	-50.38%
NeuroPace	-36.74%	-205.41%	-28.29%

Do analysts rate HYPR or NPCE?

Hyperfine currently has a consensus price target of $1.33, indicating a potential upside of 84.72%. NeuroPace has a consensus price target of $15.20, indicating a potential upside of 28.27%. Given Hyperfine's higher possible upside, equities research analysts clearly believe Hyperfine is more favorable than NeuroPace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperfine	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
NeuroPace	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Does the media prefer HYPR or NPCE?

In the previous week, Hyperfine had 9 more articles in the media than NeuroPace. MarketBeat recorded 12 mentions for Hyperfine and 3 mentions for NeuroPace. Hyperfine's average media sentiment score of 0.56 beat NeuroPace's score of 0.30 indicating that Hyperfine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperfine	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
NeuroPace	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more risk and volatility, HYPR or NPCE?

Hyperfine has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500. Comparatively, NeuroPace has a beta of 2.06, suggesting that its stock price is 106% more volatile than the S&P 500.

Do institutionals & insiders have more ownership in HYPR or NPCE?

15.0% of Hyperfine shares are owned by institutional investors. Comparatively, 78.8% of NeuroPace shares are owned by institutional investors. 29.4% of Hyperfine shares are owned by insiders. Comparatively, 22.2% of NeuroPace shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Does the MarketBeat Community prefer HYPR or NPCE?

NeuroPace received 25 more outperform votes than Hyperfine when rated by MarketBeat users. Likewise, 60.78% of users gave NeuroPace an outperform vote while only 50.00% of users gave Hyperfine an outperform vote.

Company	Underperform	Outperform
Hyperfine	Outperform Votes 6 50.00%	Underperform Votes 6 50.00%
NeuroPace	Outperform Votes 31 60.78%	Underperform Votes 20 39.22%

Which has better earnings & valuation, HYPR or NPCE?

NeuroPace has higher revenue and earnings than Hyperfine. NeuroPace is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperfine	$12.89M	4.07	-$44.24M	-$0.56	-1.29
NeuroPace	$79.91M	4.83	-$32.96M	-$0.95	-12.47

Summary

NeuroPace beats Hyperfine on 11 of the 18 factors compared between the two stocks.